ERBB2 and neoplasm: Surface HSP90 interacts with HER2 and mediates tumor cell invasiveness on breast cancer cells (60), and blocking surface HSP90 activity with a cell-impermeant inhibitor or antibodies validates this in other tumor types (61–63).